...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >The human epidermal growth factor receptor 2 (HER2)
【24h】

The human epidermal growth factor receptor 2 (HER2)

机译:人表皮生长因子受体2(HER2)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The declared "war on cancer" aimed to eradicate this disease using our knowledge of cancer cell biology to develop novel therapeutics. One such target of these novel therapies has been the human epidermal growth factor receptor 2 (HER2) gene. Unique in the approach to abolishing function of this gene coded receptor, it was the first target of new monoclonal antibody therapy targeting the extracellular receptor and now also a target of small molecule drugs against the intracellular tyrosine kinase domain. In this instance, it was also one of the first applications of personalized medicine requiring companion diagnostics. In this manuscript, we review the biology and clinical applications of HER2 as a biomarker of disease and as a therapeutic target.
机译:宣称的“抗癌战争”旨在利用我们对癌细胞生物学的了解来根除这种疾病,从而开发出新颖的疗法。这些新疗法的此类靶标之一是人表皮生长因子受体2(HER2)基因。在消除该基因编码受体功能的方法中,它是独特的,它是针对细胞外受体的新型单克隆抗体疗法的第一个靶标,现在也是针对细胞内酪氨酸激酶结构域的小分子药物的靶标。在这种情况下,它还是需要伴随诊断的个性化医学的首批应用之一。在本文中,我们回顾了HER2作为疾病的生物标志物和治疗靶标的生物学和临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号